1256565-36-2
Chemical Structure
PTC299
Synonym(s): Emvododstat
- CAS No.: 1256565-36-2
- Formula:C25H20Cl2N2O3
- Molecular Weight:467.34
IUPAC Name: 4-chlorophenyl (S)-6-chloro-1-(4-methoxyphenyl)-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indole-2-carboxylate
InChIKey: SRSHBZRURUNOSM-DEOSSOPVSA-N
SMILES: O=C(N([C@H]1C2=CC=C(OC)C=C2)CCC3=C1NC4=C3C=C(Cl)C=C4)OC5=CC=C(Cl)C=C5
Biological Activity: PTC299 is an orally active inhibitor of VEGFA mRNA translation that selectively inhibits VEGF protein synthesis at the post-transcriptional level. PTC299 is also a potent inhibitor of dihydroorotate dehydrogenase (DHODH). PTC299 shows good oral bioavailability and lack of off-target kinase inhibition and myelosuppression. PTC299 can be useful for the research of hematologic malignancies[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
PTC299 | 99.71% | PTC299 is an orally active inhibitor of VEGFA mRNA translation that selectively inhibits VEGF protein synthesis at the post-transcriptional level. PTC299 is also a potent inhibitor of dihydroorotate dehydrogenase (DHODH). PTC299 shows good oral bioavailability and lack of off-target kinase inhibition and myelosuppression. PTC299 can be useful for the research of hematologic malignancies. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.68
HY-119724ABCG2-IN-3 -
Similarity Score 0.60
HY-143487Antimalarial agent 12 -
Similarity Score 0.56
HY-159496Dyrk1A-IN-10 -
Similarity Score 0.53
HY-125059PTC-510 free base -
Similarity Score 0.53
HY-162564Antibacterial agent 221 -
Similarity Score 0.53
HY-1458415-HT2A receptor agonist-2 -
Similarity Score 0.53
HY-175210STING-IN-16 -
Similarity Score 0.52
HY-175615RSL3-NH2 -
Similarity Score 0.52
HY-175615ARSL3-NH2 hydrochloride -
Explore the MedChemAI to find more analogs
References
- [1]. Cao L, et al. Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of DihydroorotateDehydrogenase with Favorable Pharmaceutical Properties. Mol Cancer Ther. 2019 Jan;18(1):3-16. [Content Brief]
- [2]. Bender Ignacio RA, et al. Brief Report: A Phase 1b/Pharmacokinetic Trial of PTC299, a Novel PostTranscriptional VEGF Inhibitor, for AIDS-Related Kaposi's Sarcoma: AIDS Malignancy Consortium Trial 059. J Acquir Immune Defic Syndr. 2016 May 1;72(1):52-7. [Content Brief]
